Medical Advocates
Efavirenz/Tenofovir/Emtricitabine (Atripla)
 
Main Page

New and Noteworthy
Journal Citations
 Perinatal Updates
Pediatric Updates
Product Information




 
ARV Drugs Main Page Main New/Newsworthy  Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  February 09, 2015  
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
February 2015
 
 
Journal Citations
     
Animal Studies
 
  Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
 Nirogi R, Bhyrapuneni G, Kandikere V, 
Biopharm Drug Dispos. 2012 May 18.
 Abstract

General Reports
 
 

FULL-TEXT ARTICLE
 A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals.
 Moyle GJ, Orkin C, Fisher M,  et al
PLoS One. 2015 Feb 6;10(2):e0116297.
Paper

FULL-TEXT ARTICLE
 Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
 Lamorde M, Byakika-Kibwika P, Tamale WS,  et al
AIDS Res Treat. 2012;2012:105980.
 Paper

Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1.
 Oyagüez I, Casado MA, Cotarelo M, et al.
 Farm Hosp. 2009 Sep 1;33(5):247-56
 Abstract

Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet.
[No authors listed] 
Prescrire Int. 2009 Jun;18(101):105.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Atripla – HIV therapy in one pill.
 Julg B, Bogner JR.   
 Ther Clin Risk Manag. 2008 Jun;4(3):573-7.
 Paper
 
A WEEK IN REVIEW FEATURED REPORT
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
 Sánchez-de la Rosa R, Herrera L, Moreno S.
 Clin Ther. 2008 Feb;30(2):372-81.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
 Killingley B, Pozniak A.  
 Drugs Today (Barc). 2007 Jul;43(7):427-42
 Abstract

Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen.
 Mathias AA, Hinkle J, Menning M, et al 
J Acquir Immune Defic Syndr. 2007 Jul 19;
 Abstract

Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate: triple combination tablet.
 Frampton JE, Croom KF. 
Drugs. 2006;66(11):1501-12
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes: A 96-Week Analysis.
 Pozniak AL, Gallant JE, Dejesus E, et al  
J Acquir Immune Defic Syndr. 2006 Oct 12;
 Abstract
 

Efficacy
 
 
A WEEK-IN-REVIEW FEATURED ARTICLE
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis.
Behrens G, Rijnders B, Nelson M,  et al 
AIDS Patient Care STDS. 2014 Apr;28(4):168-75.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
 Cohen C, Wohl D, Arribas JR, Henry K, et al 
AIDS. 2014 Feb 6
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results.
 Zolopa A, Sax PE, Dejesus E,  et al 
J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100.
 Abstract

A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A, Sax PE, Dejesus E,  et al
J Acquir Immune Defic Syndr. 2013 Feb 7.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
 Rockstroh JK, Dejesus E, Henry K,  et al
J Acquir Immune Defic Syndr. 2013 Jan 18
 Abstract

Effectiveness and safety of a single-tablet regimen of emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in infectious diseases department.
Xerinda S, Neves N, Santos S,  et al.
J Int AIDS Soc. 2012 Nov 11;15(6):18383.
 Abstract

A WEEK-IN-REVIEW FEATURED ARTICLE
FULL-TEXT ARTICLE
 Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings.
 Campbell TB, Smeaton LM, Kumarasamy N,  et al
 PLoS Med. 2012 Aug;9(8):e1001290.
Paper

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.
 Scourfield A, Zheng J, Chinthapalli S, et al
AIDS. 2012 Mar 21 
 Abstract

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®):A Review of its Use in the Management of HIV Infection.
 Deeks ED, Perry CM
Drugs. 2010 Dec 3;70(17):2315-2338.
Abstract

Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet.
 [No authors listed] 
Prescrire Int. 2009 Jun;18(101):105.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed
HIV-1-Infected Patients.
 Dejesus E, Young B, Morales-Ramirez JO, et al
J Acquir Immune Defic Syndr. 2009 Apr 7.
Abstract
 
FULL-TEXT ARTICLE
 Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
 Pujari S, Dravid A, Gupte N, et al 
Medscape J Med. 2008;10(8):196.
 Paper
 
Adverse Events
 
  Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients.
 Pistone G, Pistone A, Sorbello D, et al
Case Rep Dermatol. 2014 May 17;6(2):145-9. 
Abstract

A WEEK IN REVIEW FEATURED REPORT
EFV/FTC/TDF-Associated Hepatotoxicity: A Case Report and Review.
 Echenique IA, Rich JD. 
AIDS Patient Care STDS. 2013 Aug 12.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Patient-Reported Symptoms on the Antiretroviral Regimen Efavirenz/Emtricitabine/Tenofovir.
Edelman EJ, Gordon K, Rodriguez-Barradas MC
AIDS Patient Care STDS. 2012 May 21.
 Abstract
 
Resistance
 
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
 Blanco JL, Montaner JS, Marconi VC, et al
AIDS. 2014 Nov 13;28(17):2531-9.
 Abstract

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
 White KL, Kulkarni R, McColl DJ,  et al
Antivir Ther. 2014 Oct 16
Abstract
 
 

Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110).
 Porter DP, Kulkarni R, Fralich T, et al
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26
Abstract

The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
 Bulteel N, Bansi-Matharu L, Churchill D, et al
J Infect. 2013 Sep 19.
 Abstract
 
Economics
 
  A WEEK IN REVIEW FEATURED REPORT
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
 Juday T, Correll T, Anene A, Broder MS,  et al 
Clinicoecon Outcomes Res. 2013 Sep 2;5:437-45.
 Abstract

Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.
Colombo GL, Di Matteo S, Maggiolo F.
Clinicoecon Outcomes Res. 2013;5:59-68
 Abstract
Perinatal Updates
 

Journal Citations
  A Quantitative Study of Factors Influencing Quality of Life in Rural Mexican Women Diagnosed With HIV.
Holtz C, Sowell R, Vanbrackle L, et al J
 Assoc Nurses AIDS Care. 2014 Apr 20.
Abstract
Pediatric Updates
 
USPHS Pediatric Antiretroviral Drug Information
 US Treatment Guidelines

ARV Drugs Main Page Main New/Newsworthy  Home Page      

Efavirenz/Emtricitabine/Tenofovir (Atripla)